Trial Profile
Phase III Study of ASP1941 -A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BRIGHTEN
- Sponsors Astellas Pharma
- 16 Sep 2011 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met. Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2011 Status changed from active, no longer recruiting to completed.